From Wikipedia the free encyclopedia
Myelitis is inflammation of the spinal cord which can disrupt the normal responses from the brain to the rest of the body, and from the rest of the body to the brain. Inflammation in the spinal cord, can cause the myelin and axon to be damaged resulting in symptoms such as paralysis and sensory loss. Myelitis is classified to several categories depending on the area or the cause of the lesion; however, any inflammatory attack on the spinal cord is often referred to as transverse myelitis.
Types of myelitis
Myelitis lesions usually occur in a narrow region but can be spread and affect many areas.
- Acute flaccid myelitis: a polio-like syndrome that causes muscle weakness and paralysis.
- Poliomyelitis: disease caused by viral infection in the gray matter with symptoms of muscle paralysis or weakness
- Transverse myelitis: caused by axonal demyelination encompassing both sides of the spinal cord
- Leukomyelitis: lesions in the white matter
- Meningococcal myelitis (or meningomyelitis): lesions occurring in the region of meninges and the spinal cord
Osteomyelitis of the vertebral bone surrounding the spinal cord (that is, vertebral osteomyelitis) is a separate condition, although some infections (for example, Staphylococcus aureus infection) can occasionally cause both at once. The similarity of the words reflects that the combining form myel(o)- has multiple (homonymous) senses referring to bone marrow or the spinal cord.
Depending on the cause of the disease, such clinical conditions manifest different speed in progression of symptoms in a matter of hours to days. Most myelitis manifests fast progression in muscle weakness or paralysis starting with the legs and then arms with varying degrees of severity. Sometimes the dysfunction of arms or legs cause instability of posture and difficulty in walking or any movement. Also symptoms generally include paresthesia which is a sensation of tickling, tingling, burning, pricking, or numbness of a person's skin with no apparent long-term physical effect. Adult patients often report pain in the back, extremities, or abdomen. Patients also present increased urinary urgency, bowel or bladder dysfunctions such as bladder incontinence, difficulty or inability to void, and incomplete evacuation of bowel or constipation. Others also report fever, respiratory problems and intractable vomiting.
Diseases associated with myelitis
Conditions associated with myelitis include:
- Acute disseminated encephalomyelitis: autoimmune demyelination of the brain causing severe neurological signs and symptoms
- Multiple sclerosis: demyelination of the brain and spinal cord
- Neuromyelitis optica or Devic's disease: immune attack on optic nerve and spinal cord
- Sjögren's syndrome: destruction of the exocrine system of the body
- Systemic lupus erythematosus: a systemic autoimmune disease featuring a wide variety of neurological signs and symptoms
- Sarcoidosis: chronic inflammatory cells form as nodules in multiple organs
- Atopy: an immune disorder of children manifesting as eczema or other allergic conditions. It can include atopic myelitis, which causes weakness.
- Immune-mediated myelopathies, heterogeneous group of inflammatory spinal cord disorders including autoimmune disorders with known antibodies
Myelitis occurs due to various reasons such as infections. Direct infection by viruses, bacteria, mold, or parasites such as human immunodeficiency virus (HIV), human T-lymphotropic virus types I and II (HTLV-I/II), syphilis, lyme disease, and tuberculosis can cause myelitis but it can also be caused due to non-infectious or inflammatory pathway. Myelitis often follows after the infections or after vaccination. These phenomena can be explained by a theory of autoimmune attack which states that the autoimmune bodies attack its spinal cord in response to immune reaction.
Mechanism of myelitis
The theory of autoimmune attack claims that a person with neuroimmunologic disorders have genetic predisposition to auto-immune disorder, and the environmental factors would trigger the disease. The specific genetics in myelitis is not completely understood. It is believed that the immune system response could be to viral, bacterial, fungal, or parasitic infection; however, it is not known why the immune system attacks itself. Especially, for the immune system to cause inflammatory response anywhere in the central nervous system, the cells from the immune system must pass through the blood brain barrier. In the case of myelitis, not only is the immune system dysfunctional, but the dysfunction also crosses this protective blood brain barrier to affect the spinal cord.
Most viral myelitis is acute, but the retroviruses (such as HIV and HTLV) can cause chronic myelitis. Poliomyelitis, or gray matter myelitis, is usually caused by infection of anterior horn of the spinal cord by the enteroviruses (polioviruses, enteroviruses (EV) 70 and 71, echoviruses, coxsackieviruses A and B) and the flaviviruses (West Nile, Japanese encephalitis, tick-borne encephalitis). On the other hand, transverse myelitis or leukomyelitis, or white matter myelitis, are often caused by the herpesviruses and influenza virus. It can be due to direct viral invasion or via immune mediated mechanisms.
Bacterial myelitis includes Mycoplasma pneumoniae, which is a common agent for respiratory tract. Studies have shown respiratory tract infections within 4–39 days prior to the onset of transverse myelitis. Or, tuberculosis, syphilis, and brucellosis are also known to cause myelitis in immune-compromised individuals. Myelitis is a rare manifestation of bacterial infection.
Fungi have been reported to cause spinal cord disease either by forming abscesses inside the bone or by granuloma. In general, there are two groups of fungi that may infect the CNS and cause myelitis - primary and secondary pathogens. Primary pathogens include the following: Cryptococcus neoformans, Coccidioides immitis, Blastomyces dermatitides, and Hystoplasma capsulatum. Secondary pathogens are opportunistic agents that primarily infect immunocompromised hosts such as Candida species, Aspergillus species, and zygomycetes.
Parasitic species infect human hosts through larvae that penetrate the skin. Then they enter the lymphatic and circulatory system, and migrate to liver and lung. Some reach the spinal cord. Parasitic infections have been reported with Schistosoma species, Toxocara canis, Echinococcus species, Taenia solium, Trichinella spiralis, and Plasmodium species.
In 2016, it was identified in Mayo clinic an autoimmune form of myelitis due to the presence of anti-GFAP autoantibodies. Immunoglobulins directed against the α-isoform of glial fibrillary acidic protein (GFAP-IgG) predicted a special meningoencephalomyelitis termed autoimmune GFAP Astrocytopathy that later was found also to be able to appear as a myelitis.
Myelitis has an extensive differential diagnosis. The type of onset (acute versus subacute/chronic) along with associated symptoms such as the presence of pain, constitutional symptoms that encompass fever, malaise, weight loss or a cutaneous rash may help identify the cause of myelitis. In order to establish a diagnosis of myelitis, one has to localize the spinal cord level, and exclude cerebral and neuromuscular diseases. Also a detailed medical history, a careful neurologic examination, and imaging studies using magnetic resonance imaging (MRI) are needed. In respect to the cause of the process, further work-up would help identify the cause and guide treatment. Full spine MRI is warranted, especially with acute onset myelitis, to evaluate for structural lesions that may require surgical intervention, or disseminated disease. Adding gadolinium further increases diagnostic sensitivity. A brain MRI may be needed to identify the extent of central nervous system (CNS) involvement. Lumbar puncture is important for the diagnosis of acute myelitis when a tumoral process, inflammatory or infectious cause are suspected, or the MRI is normal or non-specific. Complementary blood tests are also of value in establishing a firm diagnosis. Rarely, a biopsy of a mass lesion may become necessary when the cause is uncertain. However, in 15–30% of people with subacute or chronic myelitis, a clear cause is never uncovered.
Since each case is different, the following are possible treatments that patients might receive in the management of myelitis.
High-dose intravenous methyl-prednisolone for 3–5 days is considered as a standard of care for patients suspected to have acute myelitis, unless there are compelling reasons otherwise. The decision to offer continued steroids or add a new treatment is often based on the clinical course and MRI appearance at the end of five days of steroids.
Patients with moderate to aggressive forms of disease who do not show much improvement after being treated with intravenous and oral steroids will be treated with PLEX. Retrospective studies of patients with TM treated with IV steroids followed by PLEX showed a positive outcome. It also has been shown to be effective with other autoimmune or inflammatory central nervous system disorders. Particular benefit has been shown with patients who are in the acute or subacute stage of the myelitis showing active inflammation on MRI. However, because of the risks implied by the lumbar puncture procedure, this intervention is determined by the treating physician on a case-by-case basis.
Myelitis with no definite cause seldom recurs, but for others, myelitis may be a manifestation of other diseases that are mentioned above. In these cases, ongoing treatment with medications that modulate or suppress the immune system may be necessary. Sometimes there is no specific treatment. Either way, aggressive rehabilitation and long-term symptom management are an integral part of the healthcare plan.
Prospective research direction
Central nervous system nerve regeneration would be able to repair or regenerate the damage caused to the spinal cord. It would restore functions lost due to the disease.
- Engineering endogenous repair
Currently, there exists a hydrogel based scaffold which acts as a channel to deliver nerve growth-enhancing substrates while providing structural support. These factors would promote nerve repairs to the target area. Hydrogels' macroporous properties would enable attachment of cells and enhance ion and nutrient exchange. In addition, hydrogels' biodegradability or bioresolvability would prevent the need for surgical removal of the hydrogel after drug delivery. It means that it would be dissolved naturally by the body's enzymatic reaction.
- Biochemical repair
- Neurotropic factor therapy and gene therapy
- Neurotropic growth factors regulate growth, survival, and plasticity of the axon. They benefit nerve regeneration after injury to the nervous system. They are a potent initiator of sensory axon growth and are up-regulated at the lesion site. The continuous delivery of neurotropic growth factor (NGF) would increase the nerve regeneration in the spinal cord. However, the excessive dosing of NGF often leads to undesired plasticity and sprouting of uninjured sensory nerves. Gene therapy would be able to increase the NGF efficacy by the controlled and sustained delivery in a site-specific manner.
- Stem cell-based therapies
The possibility for nerve regeneration after injury to the spinal cord was considered to be limited because of the absence of major neurogenesis. However, Joseph Altman showed that cell division does occur in the brain which allowed potential for stem cell therapy for nerve regeneration. The stem cell-based therapies are used in order to replace cells lost and injured due to inflammation, to modulate the immune system, and to enhance regeneration and remyelination of axons. Neural stem cells (NSC) have the potential to integrate with the spinal cord because in the recent past investigations have demonstrated their potential for differentiation into multiple cell types that are crucial to the spinal cord. Studies show that NSCs that were transplanted into a demyelinating spinal cord lesion were found to regenerate oligodendrocytes and Schwann cells, and completely remyelinated axons.
- Myalgic encephalomyelitis – also known as chronic fatigue syndrome
- Transverse myelitis
- Kelly H (April 2006). "Evidence for a causal association between oral polio vaccine and transverse myelitis: A case history and review of the Literature". J Paediatr Child Health. 42 (4): 155–9. doi:10.1111/j.1440-1754.2006.00840.x. PMID 16630313. S2CID 25968577.
- Thomas M, Thomas J (February 1997). "Acute transverse myelitis". J la State Med Soc. 149 (2): 75–7. PMID 9055531.
- Wasay M, Arif H, Khealani B, Ahsan H (July 2006). "Neuroimaging of tuberculous myelitis: analysis of ten cases and review of literature". J Neuroimaging. 16 (3): 197–205. doi:10.1111/j.1552-6569.2006.00032.x. PMID 16808820. S2CID 23371278.
- Baum J, Solomon M, Alba A (1981). "Sarcoidosis as a cause of transverse myelitis: case report". Paraplegia. 19 (3): 167–9. doi:10.1038/sc.1981.34. PMID 7254896.
- Stenius B, Wide L, Seymour WM, Holford-Strevens V, Pepys J (March 1971). "Clinical significance of specific IgE to common allergens. I. Relationship of specific IgE against Dermatophagoides spp. and grass pollen to skin and nasal tests and history". Clin. Allergy. 1 (1): 37–55. doi:10.1111/j.1365-2222.1971.tb02446.x. PMID 4115166. S2CID 41001330.
- Yoon JH, Joo IS, Li WY, Sohn SY (October 2009). "Clinical and laboratory characteristics of atopic myelitis: Korean experience". J. Neurol. Sci. 285 (1–2): 154–8. doi:10.1016/j.jns.2009.06.033. PMID 19628231. S2CID 26571843.
- Wendebourg, M.J., Nagy, S., Derfuss, T. et al. Magnetic resonance imaging in immune-mediated myelopathies, J Neurol (2019). https://doi.org/10.1007/s00415-019-09206-2
- "Transverse Myelitis Association - Advocating for individuals with rare neuro-immune disorders". The Transverse Myelitis Association. Retrieved 21 March 2018.
- Mihai C, Jubelt B (December 2012). "Infectious myelitis". Curr Neurol Neurosci Rep. 12 (6): 633–41. doi:10.1007/s11910-012-0306-3. PMID 22927022. S2CID 7920572.
- Sechi E, Morris PP, McKeon A, Pittock SJ, Hinson SR, Weinshenker BG, Aksamit AJ, Krecke KN, Kaufmann TJ, Jolliffe EA, Zalewski NL, Zekeridou A, Wingerchuk DM, Jitprapaikulsan J, Flanagan EP (July 2018). "Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis". J. Neurol. Neurosurg. Psychiatry. 90 (4): 488–490. doi:10.1136/jnnp-2018-318004. PMID 30032117. S2CID 51707471.
- Kitley JL, Leite MI, George JS, Palace JA (March 2012). "The differential diagnosis of longitudinally extensive transverse myelitis". Mult. Scler. 18 (3): 271–85. doi:10.1177/1352458511406165. PMID 21669935. S2CID 23436434.
- "Transverse Myelitis (TM) Treatment – Johns Hopkins Transverse Myelitis Center". hopkinsmedicine.org. Retrieved 21 March 2018.
- Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG (December 2011). "Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 77 (24): 2128–34. doi:10.1212/WNL.0b013e31823dc535. PMID 22156988.
- Karumbaiah, L., Bellamkonda, R.. Neural Tissue Engineering.
- Altman J, Das GD (June 1965). "Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats". J. Comp. Neurol. 124 (3): 319–35. doi:10.1002/cne.901240303. PMID 5861717. S2CID 14121873.
- Reynolds BA, Weiss S (March 1992). "Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system". Science. 255 (5052): 1707–10. Bibcode:1992Sci...255.1707R. doi:10.1126/science.1553558. PMID 1553558. S2CID 17905159.
- Rowland JW, Hawryluk GW, Kwon B, Fehlings MG (2008). "Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon". Neurosurg Focus. 25 (5): E2. doi:10.3171/FOC.2008.25.11.E2. PMID 18980476.
- Keirstead HS, Ben-Hur T, Rogister B, O'Leary MT, Dubois-Dalcq M, Blakemore WF (September 1999). "Polysialylated neural cell adhesion molecule-positive CNS precursors generate both oligodendrocytes and Schwann cells to remyelinate the CNS after transplantation". J. Neurosci. 19 (17): 7529–36. doi:10.1523/jneurosci.19-17-07529.1999. PMC 6782511. PMID 10460259.